Powered by
Sponsored by

COVID vaccinations for children could start from September: AIIMS chief

This will help break the chain of transmission further

42DrGuleria4 Dr Randeep Guleria | Sanjay Ahlawat

Speaking to NDTV, AIIMS chief Randeep Guleria stated that India is likely to start vaccinating children by September. "I think Zydus has already done the trials and they're waiting for the emergency authorisation. The Bharat Biotech's Covaxin trials should be over by August or September, and by that time we should get an approval. Pfizer vaccine has been already approved by the FDA," he said, reported the publication.

Which are the vaccines approved for children? Zydus Cadila, which is developing DNA vaccines, has concluded its clinical trial for between the age group of 12 to 18 years of age and, subject to the statutory permissions, it may be available in near future for children of the age group of 12 to 18 years of age. The Drugs Controller General of India, on May 12, had permitted Bharat Biotech to conduct clinical trials of its vaccine Covaxin on volunteers between 2 to 18 years of age, and the enrolment process for this trial has also begun.

As of Friday, the cumulative COVID-19 vaccine doses administered in the country has exceeded 42.75 crore, the Union health ministry stated. Nearly 38,87,028 vaccine doses have been administered on Friday, according to the 7pm provisional report. The ministry said 18,09,954 vaccine doses were administered as first dose and 1,92,363 vaccine doses given as second dose in the age group 18-44 years on Friday. Cumulatively, 13,52,21,119 persons in the age group 18-44 years across states and union territories have received their first dose and total 57,54,908 have received their second dose since the start of phase-3 of the vaccination drive.

Madhya Pradesh, Maharashtra and Uttar Pradesh have administered more than 1 crore cumulative doses of COVID-19 vaccine in the age group 18-44 years.

đź“Ł The Week is now on Telegram. Click here to join our channel (@TheWeekmagazine) and stay updated with the latest headlines